Dentons Biochemical Technology Insider Reveals Patent in The Netherlands

the group member company concerned recently received a request from the plaintiff's legal counsel through its Dutch legal counsel for compensation of more than 2,200,000 euros for the infringementAfter seeking legal advice from the Legal Counsel of the Netherlands, the group member companies concerned believe that they have reasonable grounds to challenge the basis for the calculation of compensationTherefore, the group member company concerned will not settle the claim at this stageIt is therefore expected that the plaintiff will commence a compensation assessment proceedings for the assessment of claimsXX3
This announcement was made by Dentons Biochemical Technology Group Limited ("the Company") in accordance with Section 13.09 of the Securities Listing Rules of the Stock Exchange limited by the Stock Exchange of Hong Kong limited by 13.09 and the inside information provisions of Section XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)XX3
I have the honour to mention the announcements issued by the Company on 11 April 2011, 20 May 2013, 28 October 2013 and 25 March 2014 (the "Previous Notice")As disclosed in the previous announcement, the relevant Dutch court has ruled that the Company and its other wholly-owned subsidiaries ("the Group Member Companies") have violated ("violations") of three counts of Ajinomoto Cofor the submission in the Netherlands of the sale, import and sale of L-Lysine products of the Group Member CompanyInc(along with Ajinomoto Eurolysine S.A.S.) is a European patent ("Relevant Patents")," ep 0.733.710 (titled "Process for Production of L-Production L-Ly" sine by Fermentation), EP 0.733.712 (titled "Process for Production of Substances(Process for Production a Substance)") and EP 0.796.912 (titled "New lysine deglutinase gene and procedure for the production of L-Lysine( Lysine Decarboxylase Gene and Process For Producing L-Lysine)XX3
The Group Member Company has recently received a request from the plaintiff's legal counsel through its Dutch legal counsel for compensation of more than EUR 2,200,000 ("claim compensation") and payment of approximately EUR 260,000 to EUR 290,000 in the costs of the Independent Auditor as described in the Company's announcement on 25 March 2014After seeking legal advice from the Legal Counsel of the Netherlands, the group member companies concerned believe that they have reasonable grounds to challenge the basis for the calculation of compensationTherefore, the group member company concerned will not settle the claim at this stageIt is therefore expected that the plaintiff will commence a compensation assessment proceedings for the assessment of claimsThe Group member companies concerned have also requested the plaintiff, through its Legal Counsel in the Netherlands, to provide a detailed assessment of the costs of the independent auditorsXX3
In the event of any significant development involving the above legal proceedings, the Company will make a separate announcementXX3
Shareholders and interested investors must exercise caution in the trading of the Company's securitiesXX3the group member company concerned recently received a request from the plaintiff's legal counsel through its Dutch legal counsel for compensation of more than 2,200,000 euros for the infringementAfter seeking legal advice from the Legal Counsel of the Netherlands, the group member companies concerned believe that they have reasonable grounds to challenge the basis for the calculation of compensationTherefore, the group member company concerned will not settle the claim at this stageIt is therefore expected that the plaintiff will commence a compensation assessment proceedings for the assessment of claimsXX3
　　This announcement was made by Dentons Biochemical Technology Group Limited ("the Company") in accordance with Section 13.09 of the Securities Listing Rules of the Stock Exchange limited by the Stock Exchange of Hong Kong limited by 13.09 and the inside information provisions of Section XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) XX3
　　I have the honour to mention the announcements issued by the Company on 11 April 2011, 20 May 2013, 28 October 2013 and 25 March 2014 (the "Previous Notice") As disclosed in the previous announcement, the relevant Dutch court has ruled that the Company and its other wholly-owned subsidiaries ("the Group Member Companies") have violated ("violations") of three counts of Ajinomoto Co for the submission in the Netherlands of the sale, import and sale of L-Lysine products of the Group Member Company Inc (along with Ajinomoto Eurolysine S.A.S.) is a European patent ("Relevant Patents")," ep 0.733.710 (titled "Process for Production of L-Production L-Ly" sine by Fermentation), EP 0.733.712 (titled "Process for Production of Substances(Process for Production a Substance)") and EP 0.796.912 (titled "New lysine deglutinase gene and procedure for the production of L-Lysine( Lysine Decarboxylase Gene and Process For Producing L-Lysine) XX3
　　The Group Member Company has recently received a request from the plaintiff's legal counsel through its Dutch legal counsel for compensation of more than EUR 2,200,000 ("claim compensation") and payment of approximately EUR 260,000 to EUR 290,000 in the costs of the Independent Auditor as described in the Company's announcement on 25 March 2014 After seeking legal advice from the Legal Counsel of the Netherlands, the group member companies concerned believe that they have reasonable grounds to challenge the basis for the calculation of compensation Therefore, the group member company concerned will not settle the claim at this stage It is therefore expected that the plaintiff will commence a compensation assessment proceedings for the assessment of claims The Group member companies concerned have also requested the plaintiff, through its Legal Counsel in the Netherlands, to provide a detailed assessment of the costs of the independent auditors XX3
　　In the event of any significant development involving the above legal proceedings, the Company will make a separate announcement XX3
　　Shareholders and interested investors must exercise caution in the trading of the Company's securities XX3
Share it on feed